

# Intuitive Surgical Announces \$112.6 Million Fourth Quarter Revenue, Up 56 Percent

February 1, 2007

SUNNYVALE, Calif., Feb. 1, 2007 (PRIME NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the industry leader in surgical robotics, today reported fourth quarter 2006 revenue of \$112.6 million, increasing 56% from \$72.1 million for the fourth quarter of 2005. Higher revenue was driven by increased da Vinci(r) Surgical System sales and continued growth in recurring revenue.

Fourth quarter 2006 instrument and accessory revenue increased 62% to \$33.3 million from \$20.6 million during the fourth quarter of 2005. Fourth quarter 2006 system revenue increased 53% to \$63.0 million from \$41.3 million during the fourth quarter of 2005. Fourth quarter 2006 service and training revenue increased 60% to \$16.3 million from \$10.2 million during the fourth quarter of 2005.

Revenue for the year ended December 31, 2006 totaled \$372.7 million, increasing 64% from \$227.3 million for the year ended December 31, 2005.

Three Months Ended Twelve Months Ended December 31, December 31,
Revenue
Instruments/ Accessories \$ 33.3 \$ 20.6 \$ 12.7 \$ 111.7 \$ 67.8 \$ 43.9  Systems 63.0 41.3 21.7 205.9 124.6 81.3  Service/
Training 16.3 10.2 6.1 55.1 34.9 20.2
\$112.6 \$ 72.1 \$ 40.5 \$372.7 \$227.3 \$145.4

Fourth quarter 2006 operating income was \$35.4 million compared with \$23.5 million for the fourth quarter of 2005. Operating results for the fourth quarter of 2006 included \$6.8 million of stock compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R. Excluding the \$6.8 million of non-cash stock compensation expense, fourth quarter 2006 operating income was \$42.2 million, up 80% compared with the fourth quarter of 2005.

Fourth quarter 2006 net income, including non-cash stock compensation expense, was \$23.6 million, or \$0.62 per diluted share. Excluding the impact of stock compensation expenses, fourth quarter 2006 net income was \$28.1 million, or \$0.73 per diluted share. Fourth quarter 2005 net income of \$49.5 million included a tax benefit of \$22.2 million associated with the recognition of deferred tax assets.

Net income for the year ended December 31, 2006, including non-cash stock compensation expense, was \$72.0 million, or \$1.89 per diluted share. Excluding the impact of stock compensation expenses, net income for the twelve months ended December 31, 2006 was \$88.3 million, or \$2.32 per diluted share.

Fourth quarter 2006 earnings before interest, taxes, depreciation, amortization, and non-cash stock compensation expenses (EBITDA) was \$45.1 million, up 78% compared to \$25.3 million for the fourth quarter 2005. EBITDA for the twelve months ended December 31, 2006 was \$142.4 million, up 89% compared to \$75.5 million for the twelve months ended December 31, 2005.

Intuitive ended the fourth quarter of 2006 with cash, cash equivalents and investments of \$330.3 million, up \$38.0 million from the end of the previous quarter and up \$127.6 million from fiscal year 2005.

Commenting on the announcement, Lonnie Smith, Chairman and CEO of Intuitive Surgical, said, "We are pleased with our fourth quarter revenue and earnings growth. Our financial results reflect the ongoing adoption of robotic surgery, driven by patients seeking out superior surgical outcomes enabled by the da Vinci(r) Surgical System."

The Company will also announce these results at a conference call today at 1:30 pm PDT. The dial-in numbers for the call are 877-909-3508 for participants located in the U.S. and 517-645-6051 for participants located outside the U.S. The passcode is ISRG and the meeting leader is Mr. Lonnie Smith. To access financial information that will be discussed on the call, please visit Intuitive Surgical's website at www.intuitivesurgical.com.

#### About Intuitive's Products:

The da Vinci(r) Surgical System consists of a surgeon's viewing and control console having an integrated, high-performance InSite(r) 3-D vision system, a patient-side cart consisting of three or four robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist(r) Instruments. By integrating computer-enhanced technology with surgeons' technical skills, Intuitive believes that its system enables surgeons to perform better surgery in a manner never before experienced. The da Vinci(r) Surgical System seamlessly and directly translates the surgeon's natural hand, wrist and finger movements on instrument controls at the surgeon's console outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.

The Aesop(r) Endoscope Positioner is a voice-activated robotic arm that automates the critical task of endoscope positioning, providing the surgeon

with direct control over a smooth, precise and stable view of the internal surgical field.

The Hermes(r) Control Center is a centralized system designed to voice control a series of networked "smart" medical devices.

Intuitive(r), da Vinci(r), da Vinci(r), EndoWrist(r), Hermes(r), and Aesop(r) are trademarks or registered trademarks of Intuitive Surgical, Inc.

#### About non-GAAP Financial Measures:

To supplement our consolidated financial statements presented in accordance with GAAP, Intuitive has presented the following information defined as non-GAAP financial information by the SEC: non-GAAP (pro forma) statements of operations and EBITDA. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the tables captioned "Unaudited Reconciliation of GAAP to non-GAAP Consolidated Statements of Operations" and "Unaudited Consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) Reconciliation" included in this press release.

Intuitive's management believe that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance and liquidity by excluding certain expenses that may not be indicative of core operating results. Intuitive believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Intuitive's performance and when planning, forecasting and analyzing future periods.

Intuitive has computed its non-GAAP financial measures using the same consistent method from quarter to quarter. The accompanying tables have more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forwardlooking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including the following: timing and success of product development and market acceptance of developed products; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which Intuitive Surgical operates; and unanticipated manufacturing disruptions; delays in regulatory approvals of new manufacturing facilities or the inability to meet demand for products. Words such as "estimate", "project", "plan", "intend", "expect", "anticipate", "believe" and similar expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

## INTUITIVE SURGICAL, INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA)

Three Months Ended Twelve Months Ended December 31, December 31, -----

2006 2005 2006 2005 ------

Revenue:

Products \$ 96,287 \$ 61,919 \$317,599 \$192,417 Services 16,280 10,176 55,083 34,921

\_\_\_\_\_ Total revenue

112,567 72,095 372,682 227,338

Cost of revenue:

Products 29,161 18,785 97,615 58,357 Services 8,461 4,748 27,231 15,412 \_\_\_\_\_

Total cost of revenue 37,622 23,533 124,846 73,769

Gross profit 74,945 48,562 247,836 153,569

Operating costs and expenses:

Selling, general and

administrative 31,050 20,784 110,703 67,443 Research and development 8,448 4,268 29,778 17,354

------

Total operating costs

and expenses 39,498 25,052 140,481 84,797

Income from operations 35,447 23,510 107,355 68,772

Interest and ot income, net	ther 4,181 1,928 12,783 5,035 	
Income tax ex (benefit)	income taxes 39,628 25,438 120,138 73,807 pense 15,987 (24,087)* 48,094 (20,327)*	
Net income	\$ 23,641 \$ 49,525 \$ 72,044 \$ 94,134	
Net income pe share: Basic	======= ==============================	
Diluted		
Shares used in computing basic and diluted net income per common share:  Basic 37,009 35,819 36,737 35,070		
	38,241 37,675 38,093 37,488 ======== ===========================	
* Includes a one-time deferred tax benefit of \$22.2 million related to the reversal of the tax asset valuation allowances.  INTUITIVE SURGICAL, INC.  UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP CONSOLIDATED.		
STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA)		
	Three months ended December 31,	
	2006 2005	
	123R Pro As GAAP Impact Forma Reported	
Revenue:		

Revenue:

Products \$ 96,287 \$ -- \$ 96,287 \$ 61,919 Services 16,280 -- 16,280 10,176

Total revenue 112,567 -- 112,567 72,095

Cost of revenue:

Products 29,161 (629) 28,532 18,785 Services 8,461 (399) 8,062 4,748

Total cost of revenue 37,622 (1,028) 36,594 23,533

Gross profit 74,945 1,028 75,973 48,562 % total revenue 66.6% 0.9% 67.5% 67.4%

Operating costs and expenses: Selling, general,

and administrative 31,050 (4,315) 26,735 20,784 Research and development 8,448 (1,441) 7,007 4,268

Total operating costs

and expenses 39,498 (5,756) 33,742 25,052

Income from operations 35,447 6,784 42,231 23,510 % total revenue 31.5% 6.0% 37.5% 32.6%

income, net 4,181 -- 4,181 1,928

Income before income taxes 39,628 6,784 46,412 25,438

Income tax expense

(benefit) 15,987 2,345 18,332 (24,087)\*

\_\_\_\_\_

Net income \$ 23,641 \$ 4,439 \$ 28,080 \$ 49,525

Net income per common share:

Basic \$ 0.64 \$ 0.12 \$ 0.76 \$ 1.38

----- ----- -----

Diluted \$ 0.62 \$ 0.11 \$ 0.73 \$ 1.31

Shares used in computing

basic and diluted net income per common share:

Basic 37,009 35,819

Diluted 38,241 38,241 37,675

### INTUITIVE SURGICAL, INC.

UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)

Year ended December 31,

2006 2005
-----123R Pro As
GAAP Impact Forma Reported

Revenue:

Products \$317,599 \$ -- \$317,599 \$192,417 Services 55,083 -- 55,083 34,921

\_\_\_\_\_

------

Total revenue 372,682 -- 372,682 227,338

Cost of revenue:

Products 97,615 (2,417) 95,198 58,357 Services 27,231 (1,452) 25,779 15,412

Total cost of revenue 124,846 (3,869) 120,977 73,769

Gross profit 247,836 3,869 251,705 153,569 % total revenue 66.5% 1.0% 67.5% 67.6%

Operating costs and

expenses:

Selling, general,

and administrative 110,703 (16,037) 94,666 67,443 Research and development 29,778 (5,354) 24,424 17,354

------

Total operating costs

and expenses 140,481 (21,391) 119,090 84,797

------

<sup>\*</sup> Includes a one-time deferred tax benefit of \$22.2 million related to the reversal of the tax asset valuation allowances.

Income from operations 107,355 25,260 132,615 68,772 % total revenue 28.8% 6.8% 35.6% Interest and other income, net 12,783 -- 12,783 5,035 \_\_\_\_\_

Income before income taxes 120,138 25,260 145,398 73,807

Income tax expense

(benefit) 48,094 8,962 57,056 (20,327)\*

\_\_\_\_\_

\$ 72,044 \$ 16,298 \$ 88,342 \$ 94,134 Net income 

Net income per common share:

Basic \$ 1.96 \$ 0.44 \$ 2.40 \$ 2.68

Diluted \$ 1.89 \$ 0.43 \$ 2.32 \$ 2.51

\_\_\_\_\_ \_\_\_\_

Shares used in computing basic and diluted net

income per common share:

36,737 35,070 Basic 36,737 ======= 38,093 \_\_\_\_\_ 38,093 37,488 Diluted ======= 

## INTUITIVE SURGICAL, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)

12/31/06 12/31/05

-----Cash, cash equivalents, and investments \$330,296 \$202,739

Accounts receivable, net 94,680 52,849

Inventory 24,295 15,170

Property and equipment, net 59,939 52,225

Goodwill 118,240 124,638 Deferred tax assets 31,677 40.758 Other assets 13,208 12,663

-----

Total assets \$671,790 \$501,587 

Accounts payable and other

accrued liabilities \$ 44,700 \$ 33,485 Deferred revenue 37,385 25,511

Total liabilities 82,085 58,996 Stockholders' equity 589,705 442,591 -----

Total liabilities and

stockholders' equity \$671,790 \$501,587

INTUITIVE SURGICAL, INC. UNAUDITED CONSOLIDATED EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION, AND AMORTIZATION (EBITDA) RECONCILIATION (IN THOUSANDS)

> Three Months Ended Year Ended December 31, December 31, -----

<sup>\*</sup> Includes a one-time deferred tax benefit of \$22.2 million related to the reversal of the tax asset valuation allowances.

2005 2006 2005 2006 Net income \$ 23,641 \$ 49,525 \$ 72,044 \$ 94,133 Interest and other (4,181) (1,928) (12,783) (5,035) income, net Income tax expense 15,987 (24,087) 48,094 (20,327) (benefit) Depreciation and amortization 2,831 1,791 9,773 6,727 SFAS 123R stock compensation expense 6,784 -- 25,260 ------**EBITDA** \$45,062 \$25,301 \$142,388 \$75,498 

CONTACT: Intuitive Surgical, Inc. Ben Gong 408-523-2175 Sarah Norton 408-523-2161